Literature DB >> 9486981

Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas.

Y Nambu1, S J Hughes, A Rehemtulla, D Hamstra, M B Orringer, D G Beer.   

Abstract

The Fas receptor and ligand initiate an apoptotic pathway. Alterations in this pathway within tumor cells can result in escape from apoptosis and immune surveillance. We evaluated Fas protein expression in 42 primary pulmonary adenocarcinomas, and Fas expression and function in the lung adenocarcinoma cell lines A549 and A427. Immunohistochemical analysis demonstrated Fas protein expression in 47.6% of the tumors; however, Fas-positive tumors demonstrated cytoplasmic staining without cell surface expression. Northern blot analysis indicated that levels of Fas mRNA were similar in Fas protein-positive tumors to levels in normal lung tissue, but were reduced in Fas protein-negative tumors. Soluble form Fas was not detected in the majority of these tumors either by RT-PCR or Western blot analysis. Cell surface Fas protein expression was minimal in A549 and A427 cell lines as determined by flow cytometry. Both cell lines demonstrated Fas mRNA expression by Northern blot analysis and abundant protein expression by Western blot analysis. Transfection of the Fas cDNA derived from A549 cells induced surface Fas protein in COS cells; however, stable transfection of a native Fas cDNA into A549 cells failed to induce surface Fas protein expression. Parental A549 cells and A549 cells transfected with a Fas expression vector were resistant to Fas-mediated apoptosis. Transgenic expression of a FLAG-tagged Fas cDNA in A549 cells, with visualization of the Fas-FLAG protein using confocal microscopy, demonstrated that the Fas-FLAG protein was retained within cytoplasmic portions of the cell and was not translocated to the cell surface. These findings suggest that the Fas protein is reduced or not present on the cell surface in the primary lung tumors and is sequestered within A549 tumorigenic lung cells, and these alterations directly affect the cells resistance to Fas-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486981      PMCID: PMC508662          DOI: 10.1172/JCI1692

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Isolation of DNA from biological specimens without extraction with phenol.

Authors:  G J Buffone; G J Darlington
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

2.  Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas.

Authors:  L Xerri; N Carbuccia; P Parc; F Birg
Journal:  Am J Clin Pathol       Date:  1995-10       Impact factor: 2.493

Review 3.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

4.  Human lung carcinomas express Fas ligand.

Authors:  G A Niehans; T Brunner; S P Frizelle; J C Liston; C T Salerno; D J Knapp; D R Green; R A Kratzke
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

5.  Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.

Authors:  S J Hughes; Y Nambu; O S Soldes; D Hamstra; A Rehemtulla; M D Iannettoni; M B Orringer; D G Beer
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

6.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

Authors:  G P Midis; Y Shen; L B Owen-Schaub
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

7.  Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells.

Authors:  Z Cai; R Stancou; M Körner; S Chouaib
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

8.  Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

Authors:  L B Owen-Schaub; L S Angelo; R Radinsky; C F Ware; T G Gesner; D P Bartos
Journal:  Cancer Lett       Date:  1995-07-20       Impact factor: 8.679

9.  Fas/APO-1 gene transfer for human malignant glioma.

Authors:  M Weller; U Malipiero; A Rensing-Ehl; P J Barr; A Fontana
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

10.  Fas expression and function in normal and malignant breast cell lines.

Authors:  M M Keane; S A Ettenberg; G A Lowrey; E K Russell; S Lipkowitz
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

View more
  16 in total

1.  {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-D-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line.

Authors:  Jing Wu; Hong Lu; Xiangchun Ling; Canghai Wang; Ji Rui; Aiqin Wang; Liang Qiao
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

2.  TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis.

Authors:  Stephen K Frankel; Gregory P Cosgrove; Seung-Ick Cha; Carlyne D Cool; Murry W Wynes; Benjamin L Edelman; Kevin K Brown; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-04       Impact factor: 6.914

3.  An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Authors:  Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

4.  Streptococcal pyrogenic exotoxin B-induced apoptosis in A549 cells is mediated through alpha(v)beta(3) integrin and Fas.

Authors:  Wan-Hua Tsai; Chia-Wen Chang; Yee-Shin Lin; Woei-Jer Chuang; Jiunn-Jong Wu; Ching-Chuan Liu; Pei-Jane Tsai; Ming T Lin
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

5.  Conformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domain.

Authors:  Jonathan D Suever; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Biophys J       Date:  2008-09-26       Impact factor: 4.033

6.  Trifluoperazine regulation of calmodulin binding to Fas: a computational study.

Authors:  Di Pan; Qi Yan; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Proteins       Date:  2011-06-07

7.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

8.  Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).

Authors:  Selwyn M Vickers; Nirag C Jhala; Eun-Young Ahn; Jay M McDonald; George Pan; Kirby I Bland
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

9.  Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.

Authors:  S Aggarwal; N Taneja; L Lin; M B Orringer; A Rehemtulla; D G Beer
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

10.  Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.

Authors:  Na-Hye Myong
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.